Skip to main content
    I

    Inogen Inc (INGN)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $5.63
    -0.06 (-1.05%)

    Market Cap: $147.95M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Inogen Inc (INGN) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    In the quarter ended Sep 30, 2026, Inogen reported EPS of -$0.56, below the -$0.06 estimate. It beat the EPS estimate in 7 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    75%(30/40)
    Avg Surprise
    +23.76%

    Upcoming Estimates

    Report date not yet scheduledPeriod ending Dec 31, 2026
    EPS Consensus-$0.18
    Range-$0.19 - -$0.17
    4 analysts
    Revenue Consensus
    $85.68M
    Range$81.14M - $89.46M
    4 analysts
    Report date not yet scheduledPeriod ending Mar 31, 2027
    EPS Consensus-$0.23
    Range-$0.25 - -$0.20
    2 analysts
    EPS Revisions
    1
    2
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.19-18.4%
    60d ago-$0.21-7.1%
    30d ago-$0.21-7.1%
    7d ago-$0.21-7.1%
    Current-$0.23
    Revenue Consensus
    N/A
    RangeN/A
    0 analysts

    Next Report

    INGN's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.

    INGN Earnings Call

    The latest INGN earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, INGN beat 30 and missed 10. Revenue for the quarter ended Sep 30, 2026 was $77.19M, down 2.4% from $79.09M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.56-$0.06-$0.06 - -$0.06-833.33%MissN/A10 up, 1 downNov 5, 2026$77.19M
    Jun 30, 2026-$0.14-$0.17N/A+17.65%BeatN/A10 up, 0 downAug 6, 2026$95.08M
    Mar 31, 2026-$0.14-$0.21-$0.21 - -$0.21+33.33%BeatN/A10 up, 0 downMay 7, 2026$85.11M
    Dec 31, 2025-$0.15-$0.34N/A+56.19%BeatN/A10 up, 0 downFeb 24, 2026$81.72M
    Sep 30, 2025-$0.20-$0.22N/A+9.09%BeatN/A10 up, 0 downNov 5, 2025$79.09M
    Jun 30, 2025-$0.15-$0.22N/A+31.82%BeatN/A10 up, 0 downAug 7, 2025$92.28M
    Mar 31, 2025-$0.11-$0.25-$0.25 - -$0.25+56.00%BeatN/A10 up, 0 downMay 7, 2025$82.28M
    Dec 31, 2024-$0.24-$0.49-$0.49 - -$0.49+51.02%BeatN/A10 up, 1 downFeb 25, 2025$80.08M
    Sep 30, 2024-$0.11-$0.27N/A+59.26%BeatN/A40 up, 0 downNov 7, 2024$88.83M
    Jun 30, 2024-$0.07-$0.39N/A+82.05%BeatN/A40 up, 0 downAug 6, 2024$88.77M
    Mar 31, 2024-$0.45-$0.58N/A+22.41%BeatN/A40 up, 0 downMay 7, 2024$78.03M
    Dec 31, 2023-$1.14-$0.62-$0.71 - -$0.57-83.87%MissN/A40 up, 0 downFeb 27, 2024$75.90M
    Sep 30, 2023-$0.36-$0.23N/A-56.52%MissN/A40 up, 0 downNov 7, 2023$83.97M
    Jun 30, 2023-$0.40-$0.60-$0.69 - -$0.46+33.33%BeatN/A40 up, 0 downAug 7, 2023$83.64M
    Mar 31, 2023-$0.78-$0.75-$1.01 - -$0.70-4.00%MissN/A40 up, 0 downMay 4, 2023$72.16M
    Dec 31, 2022-$0.20-$0.57-$0.70 - -$0.45+64.91%BeatN/A50 up, 0 downFeb 23, 2023$88.09M
    Sep 30, 2022-$0.42-$0.38-$0.55 - -$0.30-10.53%Miss-179.2%50 up, 0 downNov 2, 2022$105.39M
    Jun 30, 2022-$0.15-$0.33-$0.44 - -$0.28+54.55%Beat-168.2%50 up, 0 downAug 4, 2022$103.38M
    Mar 31, 2022-$0.62-$0.51-$0.64 - -$0.35-21.57%MissN/A50 up, 0 downMay 5, 2022$80.39M
    Dec 31, 2021-$1.01-$0.73-$0.79 - -$0.69-38.36%MissN/A5N/AFeb 24, 2022$76.40M
    Sep 30, 2021$0.53-$0.29-$0.50 - -$0.10+282.76%BeatN/A6N/ANov 4, 2021$93.11M
    Jun 30, 2021$0.22-$0.10-$0.17 - $0.22+320.00%Beat+83.3%6N/AAug 4, 2021$101.56M
    Mar 31, 2021-$0.03-$0.26-$0.35 - -$0.15+88.46%BeatN/A6N/AMay 4, 2021$86.93M
    Dec 31, 2020-$0.23-$0.26-$0.32 - -$0.17+11.54%BeatN/A6N/AFeb 24, 2021$35.61M
    Sep 30, 2020-$0.08-$0.09-$0.21 - $0.19+11.11%Beat-125.8%6N/ANov 4, 2020$74.33M
    Jun 30, 2020$0.12-$0.06-$0.24 - $0.20+300.00%Beat-73.3%6N/AAug 4, 2020$71.69M
    Mar 31, 2020-$0.07-$0.11-$0.12 - -$0.08+36.36%Beat-129.2%6N/AMay 5, 2020$126.86M
    Dec 31, 2019-$0.06$0.10$0.08 - $0.15-160.00%Miss-113.6%6N/AFeb 25, 2020$440.86M
    Sep 30, 2019$0.31$0.22$0.21 - $0.28+40.91%Beat-57.5%7N/ANov 5, 2019$91.76M
    Jun 30, 2019$0.45$0.49$0.41 - $0.63-8.16%Miss-30.8%7N/AAug 7, 2019$101.06M
    Mar 31, 2019$0.24$0.33$0.17 - $0.40-27.27%Miss-50.0%7N/AMay 7, 2019$90.20M
    Dec 31, 2018$0.44$0.25$0.20 - $0.35+76.00%Beat+41.9%7N/AFeb 26, 2019$265.11M
    Sep 30, 2018$0.73$0.53N/A+37.74%Beat+121.2%N/AN/ANov 6, 2018$95.29M
    Jun 30, 2018$0.65$0.44$0.42 - $0.49+47.73%Beat+71.1%7N/AAug 7, 2018$97.24M
    Mar 31, 2018$0.48$0.29$0.17 - $0.36+65.52%Beat+77.8%6N/AApr 30, 2018$79.05M
    Dec 31, 2017$0.31$0.23$0.18 - $0.29+34.78%Beat+24.0%6N/AFeb 27, 2018$63.79M
    Sep 30, 2017$0.33$0.29$0.24 - $0.33+13.79%Beat+106.3%6N/ANov 7, 2017$69.03M
    Jun 30, 2017$0.38$0.28$0.24 - $0.32+35.71%Beat+52.0%6N/AAug 3, 2017$64.12M
    Mar 31, 2017$0.27$0.14N/A+92.86%Beat+145.5%N/AN/AMay 9, 2017$52.50M
    Dec 31, 2016$0.25$0.11N/A+127.27%Beat+31.6%N/AN/AFeb 28, 2017$50.85M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.61, after -$0.87 the year before. It was $0.77 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.61N/A
    Dec 31, 2024-$0.87N/A
    Dec 31, 2023-$2.68N/A
    Dec 31, 2022-$1.39N/A
    Dec 31, 2021-$0.29N/A
    Dec 31, 2020-$0.26-127.7%
    Dec 31, 2019$0.94-59.1%
    Dec 31, 2018$2.30+78.3%
    Dec 31, 2017$1.29+67.5%
    Dec 31, 2016$0.77N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 2,400 words across 4 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20262,3784
    2026Q2Jun 30, 20264,5227
    2026Q1Mar 31, 20264,1036
    2025Q4Dec 31, 20255,5826
    2025Q3Sep 30, 20253,4846
    2025Q2Jun 30, 20254,3687
    2025Q1Mar 31, 20253,0318
    2024Q4Dec 31, 20245,0965

    2026Q3 Earnings Call

    Opening remarks

    Lorna Williams Senior Vice President of Investor Relations and Strategic Planning Thank you all for participating in today's call. Joining me are President and Chief Executive Officer, Andrew Reding, and Chief Financial Officer, Jason A. Richardson. Earlier today, Inogen released financial results for the third quarter of 2026. The earnings release is available in the Investor Relations section of the company's website along with the supplemental financial package. During today's call, we will be discussing non-GAAP financial measures that we believe will provide useful information for investors. The information is not intended to be considered in isolation or as a substitute for GAAP financial information. Reconciliations for these non-GAAP measures to the most directly comparable GAAP measures are included in today's earnings release and supplemental financial package, each of which is available in the Investor Relations section of our website. In addition, our discussion today will include forward-looking statements, including, but not limited to, expectations about our future financial and operating performance. We make these statements based on current expectations and reasonable assumptions. However, our actual results could differ due to risks and uncertainties. Please review our annual report and other SEC filings for a discussion of risk factors that could cause our actual results to differ materially from any forward-looking statements made today. Forward-looking statements made on today's call speak only as of today, and Inogen undertakes no obligation to update or revise these statements except as required by law. The company has not provided a reconciliation of forward-looking adjusted earnings metrics to the most directly comparable GAAP measures because certain items that impact net income are uncertain or outside the company's control and cannot be reasonably estimated without unreasonable effort. With that, I will turn the call over to Inogen's President and CEO, Andrew Reding.

    Andrew Reding President and Chief Executive Officer Thank you, Lorna. Good afternoon, everyone, and thank you for being with us for Inogen's third quarter 2026 earnings call. I am pleased to speak to you today as Inogen's new CEO. Before I turn to the results, I would like to share why I joined Inogen and why I am excited about what lies ahead. I came to Inogen as chief operating officer in July, after more than 30 years in medical technology, including a number of years in respiratory care. The common thread throughout my career has been growth: building commercial organizations, bringing new products to market, and scaling businesses that make a difference in the lives of patients. Most recently, I spent more than six years as chief commercial officer of Viant Medical, where I led commercial teams as the company grew to 25 facilities and hundreds of medical device customers, including many of the industry's largest.

    Frequently Asked Questions About INGN

    Did INGN beat earnings estimates last quarter?

    No. Inogen reported EPS of -$0.56 for the quarter ended Sep 30, 2026, below the -$0.06 estimate by 833.33%.

    What EPS do analysts expect from INGN next quarter?

    The consensus EPS estimate for Inogen for the quarter ending Dec 31, 2026 is -$0.18 from 4 analysts, with estimates from -$0.19 to -$0.17.

    How often does INGN beat earnings estimates?

    Inogen beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of -72.28%.